tiprankstipranks
Innovent Biologics (HK:1801)
:1801
Hong Kong Market

Innovent Biologics (1801) Income Statement

Compare
10 Followers

Innovent Biologics Income Statement

Last quarter (Q2 2024), Innovent Biologics's total revenue was ¥3.95B, an increase of 192.60% from the same quarter last year. In Q2, Innovent Biologics's net income was ¥-392.62M. See Innovent Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
¥ 6.21B¥ 4.56B¥ 4.27B¥ 3.84B¥ 1.05B
Gross Profit
¥ 4.40B¥ 3.63B¥ 3.70B¥ 3.46B¥ 922.65M
Operating Expenses
¥ 5.07B¥ 6.21B¥ 6.05B¥ 3.50B¥ 2.70B
Depreciation and Amortization
¥ 385.10M¥ 319.42M¥ 204.75M¥ 85.63M¥ 86.37M
EBITDA
¥ -660.68M¥ -1.75B¥ -2.37B¥ -704.74M¥ -1.57B
Operating Income
¥ -1.68B¥ -2.07B¥ -3.11B¥ -820.14M¥ -1.66B
Other Income/Expenses
¥ 534.89M¥ -96.54M¥ 61.63M¥ -301.53M¥ -56.86M
Pretax Income
¥ -1.14B¥ -2.17B¥ -3.05B¥ -858.71M¥ -1.72B
Net Income
¥ -1.03B¥ -2.18B¥ -3.14B¥ -998.42M¥ -1.78B
Per Share Metrics
¥ ―¥ ―¥ ―¥ ―¥ ―
Basic EPS
¥ -0.66¥ -1.46¥ -2.16¥ -0.74¥ -1.51
Diluted EPS
¥ -0.66¥ -1.46¥ -2.16¥ -0.74¥ -1.51
Weighted Average Shares Outstanding
1.56B 1.49B 1.45B 1.35B 1.18B
Weighted Average Shares Outstanding (Diluted)
1.56B 1.49B 1.46B 1.36B 1.18B
Currency in CNY

Innovent Biologics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis